In June 2026, Sciwind Biosciences reported Phase 2 SLIMMER-UP-SWITCH trial data from China showing subcutaneous ecnoglutide achieved 12.8% weight loss versus 9.5% for semaglutide at 20 weeks, 35% greater (163 patients).